Cargando…

Sarcopenia in male patients with head and neck cancer receiving chemoradiotherapy: a longitudinal pilot study

INTRODUCTION: Muscle wasting conditions such as sarcopenia may be highly prevalent in advanced head and neck cancer (HNC) patients (16–71%), with these prevalence rates substantially greater in those who have received chemo-radiotherapy (CRT). According to the updated European Working Group on Sarco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chauhan, Namrata S., Samuel, Stephen Rajan, Meenar, Niranjan, Saxena, PU Prakash, Keogh, Justin W.L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PeerJ Inc. 2020
Materias:	Clinical Trials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049254/ https://www.ncbi.nlm.nih.gov/pubmed/32149024 http://dx.doi.org/10.7717/peerj.8617

Ejemplares similares

Relationship between physical activity, objective sleep parameters, and circadian rhythm in patients with head and neck cancer receiving chemoradiotherapy: A longitudinal study
por: Gururaj, Rachita, et al.
Publicado: (2021)

Respiratory Muscle Function and Exercise Capacity in a Stage 4 Head and Neck Cancer Patient Receiving Chemoradiotherapy
por: D’Souza, Macrina, et al.
Publicado: (2020)

Feasibility and Efficacy of Inspiratory Muscle Training in Patients with Head and Neck Cancer Receiving Concurrent Chemoradiotherapy
por: Vira, Prina, et al.
Publicado: (2021)

Concurrent chemoradiotherapy using gemcitabine and nedaplatin in recurrent or locally advanced head and neck squamous cell carcinoma
por: Huo, Rui-Xue, et al.
Publicado: (2022)

The impact of sarcopenia on survival and treatment tolerance in patients with head and neck cancer treated with chemoradiotherapy
por: Bentahila, Rita, et al.
Publicado: (2022)

Prognostic Significance of Sarcopenia With Inflammation in Patients With Head and Neck Cancer Who Underwent Definitive Chemoradiotherapy
por: Cho, Yeona, et al.
Publicado: (2018)

Clinical Impact of Cachexia in Head and Neck Cancer Patients Who Received Chemoradiotherapy
por: Hayashi, Naomi, et al.
Publicado: (2021)

Chemoradiotherapy for Head and Neck Cancer
por: D’Onofrio, Ida, et al.
Publicado: (2023)

A Prospective, Longitudinal and Exploratory Study of Head and Neck Lymphoedema and Dysphagia Following Chemoradiotherapy for Head and Neck Cancer
por: Jeans, Claire, et al.
Publicado: (2022)

L-Glutamine and Survival of Patients with Locally Advanced Head and Neck Cancer Receiving Chemoradiotherapy
por: Tsujimoto, Takae, et al.
Publicado: (2023)

Effects of Exercise Training during Concomitant Chemoradiation Therapy in Head-and-Neck Cancer Patients: A Systematic Review
por: D’souza, Macrina, et al.
Publicado: (2020)

Evaluation of the Safety of Percutaneous Sensory Nerve Stimulation in Patients with Head and Neck Cancer Receiving Chemoradiotherapy
por: Hamamoto, Takao, et al.
Publicado: (2023)

The Impact of Clinical Prognosis of Viral Hepatitis in Head and Neck Cancer Patients Receiving Concurrent Chemoradiotherapy
por: Wang, Yu-Ming, et al.
Publicado: (2023)

Modeling Sarcopenia to Predict Survival for Patients With Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy
por: Hua, Xin, et al.
Publicado: (2021)

Concurrent Chemoradiotherapy without Brachytherapy in Locally Advanced Cervical Cancer
por: Kadkhodayan, Sima, et al.
Publicado: (2013)

Effect of exercise training on functional capacity & quality of life in head & neck cancer patients receiving chemoradiotherapy
por: Samuel, Stephen R., et al.
Publicado: (2013)

Genetic Factors Associated with a Poor Outcome in Head and Neck Cancer Patients Receiving Definitive Chemoradiotherapy
por: Vossen, David M., et al.
Publicado: (2019)

Randomized trial on acute toxicities of weekly vs three‐weekly cisplatin‐based chemoradiation in head and neck cancer
por: Ameri, Ahmad, et al.
Publicado: (2021)

Comparison of pulmonary function changes between patients receiving neoadjuvant chemotherapy and chemoradiotherapy prior to minimally invasive esophagectomy: a randomized and controlled trial
por: Chen, Xiaosang, et al.
Publicado: (2022)

Indian nurses’ beliefs on physical activity promotion practices for cancer survivors in a tertiary care hospital—a cross-sectional survey
por: Pai, Hritika D., et al.
Publicado: (2022)

CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study
por: Mayadev, Jyoti, et al.
Publicado: (2020)

Utility of Prophylactic Percutaneous Gastrostomy in Patients With Head and Neck Cancer Receiving Concurrent Chemoradiotherapy: A Multicenter Analysis
por: Neves, Maria Teresa, et al.
Publicado: (2023)

Chemoradiotherapy With Generic Cisplatin Formulations for Head and Neck Cancers
por: Shimada, Rie, et al.
Publicado: (2018)

Feasibility and benefits of group-based exercise in residential aged care adults: a pilot study for the GrACE programme
por: Fien, Samantha, et al.
Publicado: (2016)

Sarcopenia in head and neck cancer: A scoping review
por: Jovanovic, Nedeljko, et al.
Publicado: (2022)

Association of Gabapentin Use With Pain Control and Feeding Tube Placement Among Patients With Head and Neck Cancer Receiving Chemoradiotherapy
por: Ma, Sung Jun, et al.
Publicado: (2022)

Adjuvant chemoradiotherapy versus chemotherapy or radiotherapy in advanced endometrial cancer: a systematic review and meta-analysis
por: Winarto, Hariyono, et al.
Publicado: (2022)

First‐line cetuximab + platinum‐based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real‐world observational study—ENCORE
por: Le Tourneau, Christophe, et al.
Publicado: (2023)

Association of Sarcopenia With Toxicity and Survival in Postoperative Recurrent Esophageal Squamous Cell Carcinoma Patients Receiving Chemoradiotherapy
por: Xu, Ying-Ying, et al.
Publicado: (2021)

Comparison of vinorelbine with cisplatin in concomitant chemoradiotherapy in head and neck carcinoma
por: Devleena,, et al.
Publicado: (2010)

Chemoradiotherapy as Definitive Treatment for Elderly Patients with Head and Neck Cancer
por: Müller von der Grün, Jens, et al.
Publicado: (2018)

Current Omics Trends in Personalised Head and Neck Cancer Chemoradiotherapy
por: Marcu, Loredana G., et al.
Publicado: (2021)

Weight Loss in Post-Chemoradiotherapy Head and Neck Cancer Patients
por: Abu Zaid, Zalina, et al.
Publicado: (2022)

Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck
por: Trieu, Vanessa, et al.
Publicado: (2018)

Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck
por: Hanna, Glenn J., et al.
Publicado: (2022)

Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer
por: Hughes, Ryan T, et al.
Publicado: (2023)

Treatment Outcomes of Patients with Locally Advanced Synchronous Esophageal and Head/Neck Squamous Cell Carcinoma Receiving Curative Concurrent Chemoradiotherapy
por: Chen, Yen-Hao, et al.
Publicado: (2017)

Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer
por: Siano, Marco, et al.
Publicado: (2017)

Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma
por: Luginbuhl, Adam J., et al.
Publicado: (2022)

Commentary: Association of Sarcopenia with Toxicity and Survival in Postoperative Recurrent Esophageal Squamous Cell Carcinoma Patients Receiving Chemoradiotherapy
por: Bahat, Zumrut, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o735acg0hopqpqjobgfb03qbqo